Seroatlas · Human Serome Atlas

EGLN3

Prolyl hydroxylase EGLN3

Also known as: EGLN3_HUMAN, HIFPH3, PHD3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H6Z9
Gene: EGLN3
Ensembl: ENSG00000129521
Chromosome: 14
Canonical length: 239 aa
Protein class: Enzymes, FDA approved drug targets, Predicted intracellular proteins
Subcellular location: Cytosol

OverviewNCBI Gene

Enables peptidyl-proline 4-dioxygenase activity. Involved in protein hydroxylation. Located in cytosol and nucleus. Implicated in renal cell carcinoma. Biomarker of clear cell renal cell carcinoma. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

239 residues, UniProt reviewed canonical sequence.

>Q9H6Z9|EGLN3
     1  MPLGHIMRLD LEKIALEYIV PCLHEVGFCY LDNFLGEVVG DCVLERVKQL HCTGALRDGQ
    61  LAGPRAGVSK RHLRGDQITW IGGNEEGCEA ISFLLSLIDR LVLYCGSRLG KYYVKERSKA
   121  MVACYPGNGT GYVRHVDNPN GDGRCITCIY YLNKNWDAKL HGGILRIFPE GKSFIADVEP
   181  IFDRLLFFWS DRRNPHEVQP SYATRYAMTV WYFDAEERAE AKKKFRNLTR KTESALTED

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against EGLN3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 114 nTPM

Expression across tissuesHPA

Tissue

skin: 114 nTPM
heart muscle: 102 nTPM
urinary bladder: 51 nTPM
small intestine: 39 nTPM
blood vessel: 36 nTPM
stomach: 36 nTPM

Single-cell type

esophageal apical cells: 576 nCPM
melanocytes: 419 nCPM
urothelial cells: 272 nCPM
extravillous trophoblasts: 264 nCPM
respiratory ciliated cells: 239 nCPM
prostatic club cells: 219 nCPM

Immune cell

plasmacytoid DC: 26 nTPM
myeloid DC: 2.6 nTPM
eosinophil: 1.8 nTPM
memory CD4 T-cell: 1.2 nTPM
NK-cell: 1.1 nTPM
memory CD8 T-cell: 0.9 nTPM

Brain region

thalamus: 63 nTPM
basal ganglia: 58 nTPM
hypothalamus: 55 nTPM
cerebellum: 54 nTPM
midbrain: 53 nTPM
white matter: 47 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.93
gnomAD pLI: 0.01
gnomAD missense Z: 1.72
DepMap mean gene effect: -0.02
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of EGLN3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads EGLN3 as an antibody target. Whether an autoantibody or antibody against EGLN3 could matter depends on whether native EGLN3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

EGLN3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label EGLN3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...